secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2024-03-26T23:59:59+00:00
Accession:  0001193125-24-077613
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Korro Bio reports FY 2023 net loss of $81.2M; cash of $166.1M funds operations into 2026
--------------------------------------------------------------------------------

- Net loss of $81.2M in 2023 vs. $58.0M in 2022; R&D expenses $57.2M (up from $42.2M).
- Cash and short-term investments $166.1M as of Dec 31, 2023, compared to $55.2M at end of 2022.
- Regulatory filing for KRRO-110 in Alpha-1 Antitrypsin Deficiency on track for H2 2024.
- Preclinical data showed >50% editing using GalNAc conjugates with subcutaneous administration in mice.
- Cash runway into 2026; interim clinical readout for KRRO-110 expected in H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000119312524077613/0001193125-24-077613-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000119312524077613/d812258d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-077613

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer